Clinical trial

Study of Immunotherapy in Combination With Chemotherapy in HER2-negative Inflammatory Breast Cancer

NCT03515798

Drugs and interventions used in this trial

2 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Mapped RxNorm record Pembrolizumab Injection Normalized identity: pembrolizumab InjectionView linked drug · Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention neoadjuvant EC-paclitaxel chemotherapy Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Study of Immunotherapy in Combination With Chemotherapy in HER2-negative Inflammatory Breast Cancer

Design: INTERVENTIONAL · Status: ACTIVE NOT RECRUITING · Phase: PHASE2

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusACTIVE_NOT_RECRUITING

Study typeINTERVENTIONAL

Start date2018-08-29

PhasePHASE2

Conditions

Inflammatory Breast Cancerverified · MONDO: inflammatory breast carcinoma

Interventions

Pembrolizumab InjectionDRUG · verified · RxNorm: pembrolizumab Injection

neoadjuvant EC-paclitaxel chemotherapyDRUG

Sponsors & collaborators

Institut Paoli-Calmetteslead sponsor

MSD Francecollaborator

Oncodistinctcollaborator

Mapped research locations

ParisFrance1 ToulouseFrance1 LyonFrance1 StrasbourgFrance1 BordeauxFrance1 DijonFrance1 CaenFrance1 RouenFrance1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT03515798 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.